Bioactive BNP and NT-proBNP have already been used to predict patient prognosis in adults with left ventricular dysfunction, ischemic heart disease, and hypertrophic cardiomyopathy [13]. This evidence concerns the gene NPPB and hypertrophic cardiomyopathy.